Fol. Biol. 2004, 50, 184-193
https://doi.org/10.14712/fb2004050060184
Immunogenicity of Dendritic Cell-Based HPV16 E6/E7 Peptide Vaccines: CTL Activation and Protective Effects
References
1. R., Herd, K., Fernando, G. J., Frazer, I. J., Tindle, R.W. (1999) T-helper epitopes identified within the transforming protein of cervical cancer-associated human papilomavirus type 16. Viral Immunol. 12, 297-312.
<https://doi.org/10.1089/vim.1999.12.297>
2. , J., Zeuthen, J., Indrová, M., Bubeníková, D., Šímová, J. (1994) Kinetics and function of peritoneal exudate cells during local IL-2 gene therapy of cancer. Int. J. Oncol. 4, 13-16.
3. , M. C., Smits, H. L., Vierboom, M. P., Minmaar, R. P., deJongh, B. M., Drijfhout, J. W., terSchegget, J., Melief, C. J., Jast, W. M. (1993) Vaccination with cytotoxic T lymphocytes epitope-containing peptide proteins against a tumour induced by human papillomavirus type 16-transformed cells. Eur. J. Immunol. 23, 2242-2249.
<https://doi.org/10.1002/eji.1830230929>
4. , G. J., Khammanivong, V., Leggatt, G. R., Liu, W. J., Frazer, I. H. (2002) The number of long-lasting functional memory CD8+ T cells generated depends on the nature of the initial nonspecific stimulation. Eur. J. Immunol. 32, 1541-1549.
<https://doi.org/10.1002/1521-4141(200206)32:6<1541::AID-IMMU1541>3.0.CO;2-S>
5. , L., Walter, J., Travers, P., Stauss, H., Chain, B. W. (1995) Tumor-associated E6 protein of human papillomavirus type 16 contains an unusual H-2Kb-restricted cytotoxic T cell epitope. J. Immunol. 155, 5519-5526.
<https://doi.org/10.4049/jimmunol.155.12.5519>
6. , R. S., Targoni, O. S., Krieg, A. M., Lehmann, P. V., Harding, C. V. (1997) CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity. J. Exp. Med. 186, 1623-1631.
<https://doi.org/10.1084/jem.186.10.1623>
7. , M., Bubeník, J., Šímová, J., Vonka, V., Němečková, Š., Mendoza, L., Reiniš, M. (2001) Therapy of HPV 16-associated carcinoma with dendritic cell-based vaccines: In vitro priming of the effector cell responses by DC pulsed with tumour lysates and synthetic RAHYNIVTF peptide. Int. J. Mol. Med. 7, 97-100.
8. , M., Mikyšková, R., Jandlová, T., Vonka, V., Bubeník, J., Bieblová, J. (2003) Adjuvant cytokine treatment of minimal residual disease after surgical therapy in mice carrying HPV16-associated tumours: cytolytic activity of spleen cells from tumour regressors. Folia Biol. (Praha) 49, 217-222.
9. , H., Melchers, F. (1988) Establishment of mouse cell lines which constitutively secrete large quantities of interleukin-2, 3, 4 or 5 using modified cDNA expression vectors. Eur. J. Immunol. 18, 97-104.
<https://doi.org/10.1002/eji.1830180115>
10. , V., Liu, X. S., Liu, W, J., Rodda, S. J., Leggatt, G. R., Tindle, R. W., Frazer, I. H., Fernando, G. J. (2003) Paucity of functional CTL epitopes in the E7 oncoprotein of cervical cancer associated human papillomavirus type 16. Immunol. Cell Biol. 81, 1-7.
<https://doi.org/10.1046/j.1440-1711.2003.01130.x>
11. , K. Y, Guarnieri, F. G., Staveley OíCarroll, K. F., Levitsky, H. J., August, J.T., Pardoll, D.M., Wu, T.C. (1996) Treatment of established tumours with a novel vaccine that enhances major histocompatibility class II presentation of tumour antigen. Cancer Res. 56, 21-26.
12. , J. I., Zorina, T., Storkus, W. J., Zitvogel, L., Celluzzi, C., Falo, L. D., Melief, C. J., Ildstad, S. T., Kast, W. M., Deleo, A. B. (1995) Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat. Med. 1, 1297-1302.
<https://doi.org/10.1038/nm1295-1297>
13. , L., Bubeník, J., Indrová, M., Bieblová, J., Vonka, V., Šímová, J. (2002) Freezing and thawing of murine bone marrow-derived dendritic cells does not alter immunophenotype and antigen presentation characteristics. Folia Biol. (Praha) 48, 242-245.
14. , R., Bieblová, J., Šímová, J., Indrová, M., Jandlová, T., Vonka, V., Šmahel, M., Bubeník, J., Mendoza, L. (2003) Local tumour IFN-γ therapy of HP 16-associated tumours. Folia Biol. (Praha) 49, 26-32.
15. , H., Tahara, H., Shurin, M. R., Attanucci, J., Giezeman-Smits, K. M., Fellows, W. K., Lotze, M. T., Chambers, W. H., Bozik, M. E. (1998) Bone marrowderived dendritic cells pulsed with a tumor-specific peptide elicit effective anti-tumor immunity against intracranial neoplasms. Int. J. Cancer. 78, 196-201.
<https://doi.org/10.1002/(SICI)1097-0215(19981005)78:2<196::AID-IJC13>3.0.CO;2-9>
16. , F., Mengede, E., Camps, M., Filius, R., Melief, C. J. (1998) Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors. J. Exp. Med. 187, 693-702.
<https://doi.org/10.1084/jem.187.5.693>
17. , M. A., Feltkamp, M. C., van Veen, K. J., Melief, C. J., Kast, W. M. (1995) Dendritic cells as carriers for a cytotoxic T-lymphocyte epitope-based peptide vaccine in protection against a human papillomavirus type 16induced tumor. J. Immunother. Emphasis Tumor Immunol. 18, 86-94.
<https://doi.org/10.1097/00002371-199508000-00002>
18. , P., Chiodoni, C., Rodolfo, M., Colombo, M. P. (1996) Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumour antigen in vivo. J. Exp. Med. 183, 317-322.
<https://doi.org/10.1084/jem.183.1.317>
19. , J. P., Di Rosa, F., Matzinger, P. (1998) A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature 393, 474-478.
<https://doi.org/10.1038/30989>
20. , Z., Reznikoff, G., Dranoff, G., Rock, K. L. (1997) Cloned dendritic cells can present endogenous antigens on both MHC class I and class II molecules. J. Immunol. 158, 2723-2730.
<https://doi.org/10.4049/jimmunol.158.6.2723>
21. , M., Pendleton, C. D., Ahlers, J., Takeshita, T., Newman, M., Berzofsky, J. A. (1994) Helper-cytotoxic T lymphocyte (CTL) determinant linkage required for priming of anti-HIV CD8+ CTL in vivo with peptide vaccine constructs. J. Immunol. 152, 549-556.
<https://doi.org/10.4049/jimmunol.152.2.549>
22. , H. J., Dawies, H., Sadovnikova, E., Chain, B., Horowitz, B., Sinclair, C. (1992) Induction of cytotoxic T lymphocytes with peptides in vitro. Identification of candidate T-cell epitopes in human papilloma virus. Proc. Natl. Acad. Sci. USA 89, 7871-7875.
<https://doi.org/10.1073/pnas.89.17.7871>
23. , M., Sobotková, E., Bubeník, J., Šímová, J., Žák, R., Ludvíková, V., Hájková, R., Kovařík, J., Jelínek, F., Povýšil, C., Marinov, J., Vonka, V. (2001) Metastatic MHC class I negative mouse cells derived by transformation with human papillomavirus type 16. Br. J. Cancer 84, 374-380.
<https://doi.org/10.1054/bjoc.2000.1615>
24. , R., Fernando, G. J. P., Sterrlig, J. C., Frazer, I. H. (1991) A "public" T helper epitope of the E7 transforming protein of human papilomavirus 16 provides cognate help for several E7 B-cell epitopes from cervical cancer-associated human papilomavirus genotypes. Proc. Natl. Acad. Sci. USA 88, 5887-5891.
<https://doi.org/10.1073/pnas.88.13.5887>
25. , R. E., van der Voort, E. I., Schoenberger, S. P., Drijfhout, J. W., van Bloois, L., Storm, G., Kast, W. M., Offringa, R., Melief, C. J. (1998) Enhancement of tumor outgrowth through CTL tolerization after peptide vaccination is avoided by peptide presentation on dendritic cells. J. Immunol. 160, 4449-4456.
<https://doi.org/10.4049/jimmunol.160.9.4449>
26. , S., Ferreira Mota, S. C., Nouta, J., Johnson, M., Lipford, G. B., Offringa, R., van der Burg, S. H., Melief, C. J. (2002) Established human papillomavirus type 16expressing tumors are effectively eradicated following vaccination with long peptides. J. Immunol. 169, 350-358.
<https://doi.org/10.4049/jimmunol.169.1.350>
